Hemagglutination-Inhibition Antibodies and Protection against Influenza Elicited by Inactivated and Live Attenuated Vaccines in Children - Top-Institutions - MDSpire

Hemagglutination-Inhibition Antibodies and Protection against Influenza Elicited by Inactivated and Live Attenuated Vaccines in Children

  • By

  • Sergey Yegorov

  • Angela Brewer

  • Louis Cyr

  • Brian J Ward

  • Eleanor Pullenayegum

  • Matthew S Miller

  • Mark Loeb

  • November 6, 2024

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Centers for Disease Control and Prevention (CDC)
    Centers for Disease Control and Prevention (CDC)

    Atlanta, GA

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • Epidemiology

  • #2

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Infectious Diseases
    • Pediatrics
    • Immunology

  • #3

    University of Toronto
    University of Toronto

    Toronto, ON

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • Pediatrics

  • #4

    University of Michigan
    University of Michigan

    Ann Arbor, MI

    Key Differentiators

    • Immunology
    • Infectious Diseases
    • Vaccine Research

  • #5

    Walter Reed Army Institute of Research (WRAIR)
    Walter Reed Army Institute of Research (WRAIR)

    Silver Spring, MD

    Key Differentiators

    • Infectious Diseases
    • Vaccine Development
    • Immunology

Original Source(s)

Hemagglutination-Inhibition Antibodies and Protection against Influenza Elicited by Inactivated and Live Attenuated Vaccines in Children

  • by Sergey Yegorov, Angela Brewer, Louis Cyr, Brian J Ward, Eleanor Pullenayegum, Matthew S Miller, Mark Loeb

  • November 6, 2024

Related Content

MicroRNAs in cancer: biogenesis, biomarkers and therapeutic strategies

Enhancing cancer vaccine efficacy via electrostatic engineering of an FcγR-targeted protein

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma